
|Articles|April 16, 2014
- Melanoma (Issue 2)
- Volume 2
- Issue 1
An Overview of Immune Checkpoint Blockade
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Advertisement
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, explains immune checkpoint blockade.
Read more about immunotherapies and combination strategies for the treatment of melanoma > >
Articles in this issue
about 12 years ago
Sequencing Strategies in Treating Patients With Melanomaabout 12 years ago
Research Into Newer Agents Under Way for NRAS Melanomaabout 12 years ago
New Crop of Combination Strategies Growing for Melanomaabout 12 years ago
In Practice: Combination Therapies in Metastatic Melanomaabout 12 years ago
New and Emerging Therapies for Metastatic Melanomaabout 12 years ago
Mutation Tests in Melanoma Crucial for Treatmentabout 12 years ago
What’s Next With Next-Generation BRAF Inhibitors?Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































